UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 4,700 shares, a growth of 2,250.0% from the December 15th total of 200 shares. Based on an average trading volume of 13,700 shares, the days-to-cover ratio is currently 0.3 days.

UCB Stock Performance

Shares of OTCMKTS:UCBJY traded down $1.94 on Monday, reaching $97.89. The company's stock had a trading volume of 13,082 shares, compared to its average volume of 10,297. UCB has a 52-week low of $44.26 and a 52-week high of $100.66. The stock's 50-day moving average is $96.71 and its two-hundred day moving average is $90.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.